Study Evaluates G-CSF Use in Elderly Patients With Non-Hodgkin Lymphoma

Granulocyte colony-stimulating factors (G-CSFs) were effective in preventing outpatient encounters for fever and infection in elderly patients.
Granulocyte colony-stimulating factors (G-CSFs) were effective in preventing outpatient encounters for fever and infection in elderly patients.

Granulocyte colony-stimulating factors (G-CSFs) were effective in preventing outpatient encounters for fever and infection in elderly patients with non-Hodgkin lymphoma, but not inpatient encounters or deaths during cycle 1, according to a study published online ahead of print in the journal Supportive Care in Cancer.1

Clinical trials have demonstrated the efficacy of prophylactic G-CSF among elderly patients with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-based chemotherapy, and G-CSFs are recommended in cancer treatment guidelines.

Therefore, researchers at the University of Texas MD Anderson Cancer Center in Houston, Texas, sought to evaluate guideline adherence and the effectiveness of G-CSFs in the general US population.

For the study, investigators analyzed data from inpatient and outpatient claims belonging to 5884 patients with non-Hodgkin lymphoma diagnosed between 2001 and 2007 who were older than 65 years and received CHOP-based chemotherapy.

Results showed that G-CSF use within 7 days of the first dose of chemotherapy increased from 32% in 2001 to 72% in 2007.

Researchers found that patients who received G-CSFs were significantly less likely to have outpatient encounters for infection compared with those who did not receive early G-CSFs (P<.0001).

In contrast, there was no statistically significant difference in inpatient encounters for infections between those who did and those who did not receive early G-CSFs (P=.2). The study also demonstrated no association between G-CSF use and mortality during cycle 1 of chemotherapy.

REFERENCE

1. Elting LS, Xu Y, Chavez-MacGregor M, Giordano SH. Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness [published online ahead of print January 21, 2016]. Supp Care Cancer. doi:10.1007/s00520-016-3079-4.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs